Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study checks Brigatinib's performance in ALK-Positive lung cancer

NCT ID NCT05735327

Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug in everyday hospital settings. No new treatment is given—just data collection during regular visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brigatinib
What this could lead to
If successful, this study could confirm that brigatinib is effective in everyday clinical practice for ALK-positive lung cancer, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is small (50 participants) and only tracks outcomes, not testing a new approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants diagnosed with ALK positive NSCLC who received brigatinib in first-line treatment in Poland.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Adult (aged ≥18) ALK positive NSCLC participants receiving brigatinib as a first-line treatment in the scope of NDP. 2. Participants willing to participate in the study and signed ICF. Exclusion Criteria 1. Current or planned participation in an interventional clinical trial for ALK positive non-small cell lung cancer (NSCLC). 2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

Contacts and locations

Locations

  • Centrum Onkologii im.Prof. F. Lukaszczyka w Bydgoszczy

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Centrum Pulmonologii i Torakochirurgii w Bystrej

    Bystra, Slskie, 43-360, Poland

  • Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii

    Wroclaw, Dolnoslskie, 53-413, Poland

  • Instytut Gruzlicy i Chorob Pluc

    Warsaw, Masovian Voivodeship, 01-138, Poland

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie

    Krakow, Lesser Poland Voivodeship, 31-202, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Panstwowy Instytut Badawczy

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie- Panstwowy Instytut Badawczy Oddzial w Krakowie

    Krakow, Lesser Poland Voivodeship, 31-115, Poland

  • Podkarpackie Centrum Chorob Pluc

    Rzeszów, Podkarpackie Voivodeship, 35-241, Poland

  • SPZOZ Uniwersytecki Szpital Kliniczny nr 2 im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Lodzi Centralny Szpital Weteranow

    Lodz, Łódź Voivodeship, 90-549, Poland

  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

    Lublin, Lublin Voivodeship, 20-954, Poland

  • Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu.

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu

    Poznan, Greater Poland Voivodeship, 60-569, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.